Pancreatic Cancer Clinical Trials in Maumee, Ohio

5 studies are recruiting for pancreatic cancer in Maumee, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of atebimetinib in combination with modified GnP compared with SOC GnP alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Taylor Cancer Research Center, Maumee, Ohio
    Locations
    48 in total
    Run by
    Immuneering Corporation

    See if you can join NCT07562152 on ClinicalTrials.gov

  2. Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Taylor Cancer Research Center, Maumee, Ohio
    Locations
    74 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07252232 on ClinicalTrials.gov

  3. Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

    The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Taylor Cancer Research Center, Maumee, Ohio
    Locations
    49 in total
    Run by
    Revolution Medicines, Inc.

    See if you can join NCT07491445 on ClinicalTrials.gov

  4. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage
    Not phased
    Ages
    18 to 130
    Site
    Research Site, Maumee, Ohio
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

  5. VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

    This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curat…

    Stage
    Phase 1
    Ages
    18 to 80
    Site
    Taylor Cancer Research Center (site 204), Maumee, Ohio
    Locations
    15 in total
    Run by
    VM Oncology, LLC

    See if you can join NCT03556228 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.